AIIMS Delhi Redevelopment: NBCC sells commercial space in South Delhi for Rs 273 crore

New Delhi: NBCC (India) Ltd has e-auctioned about 61,000 square feet of commercial area in South Delhi for Rs 273 crore for constructing residential units for the faculty and staff of the All India Institute of Medical Sciences (AIIMS) New Delhi. 

The property is located at Ayurvigyan Nagar, South Delhi. The amount will be used for the construction of housing for the faculty and staff members of AIIMS Delhi.

The transaction is valued at Rs 272.68 crore, it added. 

Also Read:Virtual autopsy at Delhi AIIMS now a nodal centre for other such institutes

The buyer Grid Controller of India Ltd, a PSU under the Ministry of Power, has secured this deal at a basic sale price of Rs 36,000 per square feet.

This commercial space is part of the ambitious redevelopment project spearheaded by NBCC for the All India Institute of Medical Sciences (AIIMS) Delhi.

As per a media report in the Business Standard, The proceeds from the sale will be utilized for constructing residences for AIIMS Delhi faculty and staff. The project, known as Grande Rue, offers parking for 150 cars across 3 levels of basement and comprises ground and 3 storeys of commercial space. Centrally located in the prime area of South Delhi, it features good connectivity and is nestled within the city’s business hub.

Medical Dialogues team had earlier reported that Prime Minister Narendra Modi virtually inaugurated the 960-bed All India Institute of Medical Sciences (AIIMS) Kalyani in West Bengal’s Nadia district. West Bengal Governor CV Ananda Bose and Union ministers Sarbananda Sonowal, Santanu Thakur, Subhas Sarkar, Nishit Pramanik and John Barla attended the inauguration event from the AIIMS campus. AIIMS Kalyani, the OPD of which has been operational since 2019, is spread over 179.8 acres of land and currently serves around 2,000 patients daily. 

The institute has already inducted around 500 MBBS and 200 nursing students and also started postgraduate and para-medical training initiatives. 

Powered by WPeMatico

AbbVie, OSE Immunotherapeutics collaborate to develop novel monoclonal antibody for Chronic Inflammation

North Chicago, Ill.: AbbVie Inc. and OSE Immunotherapeutics SA, a clinical-stage immunotherapy company, have announced a strategic partnership to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in the pre-clinical development stage.

OSE-230 is a first-in-class monoclonal antibody designed to activate ChemR23, a G-Protein Coupled Receptor (GPCR) target. Activation of ChemR23 may offer a novel mechanism for the resolution of chronic inflammation, modulating functions of both macrophages and neutrophils.

“This collaboration underscores our commitment to expanding our immunology portfolio with the ultimate goal of improving the standard of care for patients living with inflammatory diseases globally,” said Jonathon Sedgwick, Ph.D., senior vice president and global head of discovery research, AbbVie. “By leveraging our expertise in immunology drug development, we look forward to advancing OSE-230, which offers a novel mechanism-of-action to treat chronic inflammation.”

“We are very pleased to collaborate with AbbVie, a global leader in the development and commercialization of innovative medicines, to drive our OSE-230 program forward,” said Nicolas Poirier, chief executive officer, OSE Immunotherapeutics. “This partnership represents a major milestone in our company’s progress and recognizes the value of our innovative R&D capabilities. I would like to thank all our employees who helped us reach this milestone through dedication and hard work.”

Under the terms of the agreement, AbbVie will receive an exclusive global license to develop, manufacture and commercialize OSE-230. OSE Immunotherapeutics will receive a $48 million upfront payment and will be eligible to receive up to an additional $665 million in clinical development, regulatory and commercial milestones. In addition, OSE Immunotherapeutics will be eligible to receive potential tiered royalties on global net sales of OSE-230.

The transaction is subject to the satisfaction of customary closing conditions, including the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

Read also: AbbVie, Tentarix collaborate to develop conditionally-active, multi-specific biologics for oncology, immunology

Powered by WPeMatico

Rare case of Half Uterus: Doctors at CK Birla Hospital successfully treats 27-year-old woman

Gurugram: In a groundbreaking medical achievement, doctors here on Thursday said they have successfully treated an extremely rare case of half uterus, known as adenomyosis in a non-communicating rudimentary horn – the first-ever in India. 

“This case is the second reported worldwide, with the first case documented at the Lebanese American University Center in July 2021,” said doctors at C.K. Birla Hospital, Gurugram, in a statement. 

The patient, a 27-year-old woman, sought medical attention due to pelvic pressure, constant pain on the right side of her lower abdomen and pelvis. She was also unable to conceive.  

Also Read:4.5 kg tumour removed from patient’s breast at CK Birla Hospital

Clinical examinations revealed a large firm lump which deviated to the right side of the lower abdomen. The doctors initially suspected a fibroid. But detailed diagnostic hysteroscopy and robotic myomectomy (adenomyoma removal) with chromopertubation revealed that the woman had a left unicornuate uterus with adenomyosis in the non-communicating right horn, attached to a large fibroid-like mass.

This challenging anomaly required meticulous dissection and extraction, taking care to preserve surrounding structures like the intestines and urinary bladder, the doctors said.

“The adenomyoma in the non-communicating horn presented a unique challenge. With careful dissection, we successfully removed the adenomyoma, saving the ureter on the right side. The rarity of a functioning non-communicating rudimentary horn, coupled with adenomyosis, makes this case exceptional. The successful treatment involved a complete robotic-assisted excision of the entire horn, leading to significant improvement in the patient’s condition,” Dr Aruna Kalra, Director, Obstetrics and Gynaecology, at the hospital, said.

“The final histopathology confirmed the presence of adenomyosis in the rudimentary horn, adding a valuable contribution to the limited cases reported globally. The clinical presentation of such cases can vary from mild pain to complications such as pelvic pain, endometriosis, or obstetrical issues like preterm delivery and ectopic pregnancy,” Dr Kalra added.

The patient was discharged the next day and is expected to begin her fertility journey soon, the doctor said.

Powered by WPeMatico

Diploma in Dental Hygiene and Dental Mechanics 2024-2025: AIIMS Kalyani releases prospectus for Admission, all details here

West Bengal- The All India Institute of Medical Sciences (AIIMS), Kalyani, West Bengal, has issued a prospectus for enrollment in the Diploma programs for Dental Hygiene and Dental Mechanics for the academic session 2024-2025.

Department of Dentistry, AIIMS, Kalyani has hence invited applications for a Diploma in Dental Hygiene and a Diploma in Dental Mechanics.

DETAILS OF COURSE

Duration- 2 years (Regular- Full time).

Admission- January & July (Bi-annual).

DISTRIBUTION OF SEATS

There are total 04 seats for each course and the distribution of seats will be as per the constitutional reservation of the Government of India.

Course

No. of Seats

Category

Diploma in Dental Hygiene

02

02 (UR)

Diploma in Dental Mechanics

02

01 (UR) & 01 (OBC)

DETAILS OF ENTRANCE EXAMINATION

Examination Centre- All India Institute of Medical Sciences Kalyani, West Bengal.

Duration- 02 hours.

Pattern of Questions- Multiple Choice Questions (MCQs).

Medium of Entrance Examination- English.

Total Marks- 100 Marks (Each question carrying ‘1’ mark) and without Negative Marking.

DISTRIBUTION OF NUMBERS

Sl. No.

Subject

Questions

1

Biology

40

2

Physics

20

3

Chemistry

20

4

English

10

5

General Knowledge

10

FEE DETAILS

Fees particulars

Amount to be paid

Time of payment

Remark

Application fees for the entrance examination

Rs. 500/-

Rs. 250/- (For SC/ST)

During the submission of the application

Not refundable

Course fees

Rs. 2000/-

During admission

Not refundable

Caution deposit

Rs. 5000/-

During admission

Refundable on completion/quitting of the course

Final Examination fees

Rs. 500/-

During the Final examination of the course

Not refundable

MODE OF PAYMENT OF APPLICATION FEES

The application fee should be deposited in the following account and the payment receipt should be sent along with the hard copy of the application form.

Title Name

AIIMS Kalyani Internal Resources Account

Account Number

41277688529

Name of the Bank

State Bank of India

Branch

AIIMS Kalyani (Code-63963)

IFSC Code

SBIN0063963

MICR

700002838

ELIGIBILITY

Any Indian citizen who has completed 10+2 standard with science subjects i.e. Biology, Physics, Chemistry and English is eligible to apply for the course. Biology is compulsory among all the subjects to be an eligible candidate.

AGE LIMIT

The age of the candidate should be a minimum of 17 years to a maximum of 30 years however, age should be determined as per the entry in the matriculation or its equivalent certificate. Furthermore, age relaxation can be considered under the following categories:

1 5 years for ‘Physically Challenged’ candidates.

2 5 years relaxation for SC/ST category.

3 3 years relaxation for OBC category.

GENERAL GUIDELINES

1 Interested applicants satisfying the eligibility criteria in all respects may submit their applications along with required documents by post/courier/registered/speed post.

2 Candidates must ensure that the hard copy of their application and self-attested copies of other relevant documents should reach the Institute within 10 days from the last date of application.

3 Signed hard copies of the application along with all certificates/documents should be sent through speed post/courier etc. within the stipulated period, otherwise, the candidature of the applicant will not be considered.

4 Applicants have to paste their passport-size photograph with a cross mark without covering their face.

5 Scanned copies of both the application and payment receipt must also be sent to the website of the AIIMS Kalyani Faculty Exam Section.

The application will be considered invalid in the following situations:

1 If only an online application has been submitted but the hard copy has not been received within the last date.

2 In no case will the application be considered after the last date.

3 Incomplete application form does not have the applicant’s signature.

4 Applications without a passport photograph or photocopied photograph will not be considered.

5 Application forms without required certificates/documents.

6 The Institute does not take any responsibility for any delay or loss of application form or correspondence in postal/courier transit.

7 Any kind of publicity related to any applicant during examination and counselling.

DOCUMENTS

1 10th Standard passing certificate.

2 12th Standard / Higher secondary passing certificate.

3 Caste certificate issued by the appropriate authority (for OBC and EWS candidates the certificate must be within a validity period of one year).

4 Character Certificate issued by the Head of the Institution last attended.

5 The copy of the Aadhaar Card.

The candidate should ensure that the photograph fixed on the application form is recent and not taken more than 6 months before the date of application.

SELECTION PROCEDURE

Admissions will be made strictly in order of merit based on weighted marks i.e. 50% of the total marks in the entrance examination. If more than one candidate has the same marks in the entrance examination, then the selection will be based on:

1 The minimum number of wrong answers attempted.

2 Seniors in age shall be given preference.

However, the decision of the competent authority will be the final decision regarding selection.

IMPORTANT TENTATIVE DATES

Sr.no

Dates

July session

A.

Advertisements to be published on the website

1st March

B.

Submission of Application form & examination fee closure

15th April

C.

Publication of eligibility list

15th May

D.

Conducting entrance examination in collaboration with IT section (date to be fixed each time)

1st week of June

E.

Publication of result on website (date to be fixed each time)

2nd week of June

F.

Submission of course fees & admission (date to be fixed each time)

3rd & 4th week of June

RULES OF ADMISSION

1 The Diploma in Dental Hygienist and Dental Mechanics Courses are full-time courses with two years duration, prescribed and controlled by the Dental Council of India. These courses are conducted at the All India Institute of Medical Sciences, Kalyani. These courses and examinations are conducted in English language.

2 Admission to these courses is open only to Indian Nationals.

3 No stipend and accommodation will be provided by the institution to any candidate.

4 The candidate applying for these courses must have passed the 12th standard / Higher Secondary/ equivalent examination with Biology, Physics, Chemistry & English subjects, from any recognised institution in India.

5 Selection of the candidates will be done strictly based on merit.

6 The candidates belonging to the following backward class categories i.e., SC, ST, OBC, will be required to submit the Xerox copy of the caste validity certificate at the time of submission of documents which will be physically verified at the time of the admission process, failing which the category claimed, will not be granted and the candidate will be treated as a general candidate.

7 The counselling will be done as per the merit list on the scheduled date.

8 Medical check-ups will be done at AIIMS Kalyani before joining the candidates and the medically unfit individuals will not be allowed to join the course.

9 All certificates in original must be produced at the time of admission. If any disparity is found in the original documents admission will be cancelled. Similarly, any request for an extension in the period for submission of the same will not be entertained.

10 The selected candidates will have to give an undertaking in writing to abide by the discipline rules and regulations of the Institution.

11 Details of the tentative Merit List as well as the date of the Interview will be displayed on AIIMS Kalyani’s official website.

12 All the candidates are instructed to visit the AIIMS Kalyani website regularly for any communications and further information. No individual communication will be made.

13 The selected candidate must join the Institution, on or before the date prescribed by the competent authority, failing which his/ her admission stands cancelled.

14 The student while studying in these courses, if found indulging in anti-national activities, unlawful activities or ragging in any form, contrary to the provisions of relevant Acts and Laws enforced by the Government, will be liable to be expelled from the Institution.

To view the official notice, click the link below

Powered by WPeMatico

AIIMS Delhi released Time Table for BSc Hons Nursing Phase I, IV Exams 2024

New Delhi- The All India Institute of Medical Sciences (AIIMS) Examination Section has issued a notice detailing the schedule for Phase I and IV (Regular) professional exams for B.Sc Nursing Hons.

The Phase I theory exam is set to take place from the 11th to the 24th of May 2024, while Phase IV will commence from the 6th to the 13th of May 2024. Both exams will start from 2:00 PM to 5:00 PM on the 1st floor of the Examination Section in Convergence Block AIIMS, New Delhi. Meanwhile, candidates are advised to contact either the college or the concerned department for practical exams of Phase I and IV.

SCHEDULE OF PHASE-I

Date

Day

Subject

Paper No.

Venue & Time of Theory

11.05.2024

Saturday

(A) Anatomy (B) Physiology

I

Examination Section
First Floor
Convergence Block
AIIMS, New Delhi

02:00 PM
to
05:00 PM

13.05.2024

Monday

(A) Nutrition (B) Biochemistry

II

15.05.2024

Wednesday

Nursing Foundation

III

20.05.2024

Monday

Psychology

IV

22.05.2024

Wednesday

Microbiology

V

24.05.2024

Friday

English

VI

*

Practical

Nursing Foundation

IX

Dates for Practical Examination
Contact the College of
Nursing/concerned Department.

SCHEDULE OF PHASE-IV

Date

Day

Subject

Paper No.

Venue & Time of Theory

06.05.2024

Monday

Midwifery and Obstetrical Nursing

I

Examination Section
First Floor
Convergence Block
AIIMS, New Delhi

02:00 PM
to
05:00 PM

08.05.2024

Wednesday

Community Health Nursing-II

II

10.05.2024

Friday

Nursing Research & Statistics

III

13.05.2024

Monday

Management of Nursing Services & Education

IV

*

Practical-I

(Midwifery & Obstetrical Nursing)

V

Dates for Practical Examination
Contact the College of
Nursing/concerned Department

Practical-II

Community Health Nursing

VI

IMPORTANT POINTS

1 All the candidates are advised to deposit their examination fee before the last date of registration which will be announced later and take a printout of the admit card from the website.

2 No candidate will be allowed to enter the examination hall without an admit card and identity card.

3 Students are urged to regularly visit the AIIMS Examination Section website “Student Tab” for all the latest information.

To view the official notice, click the link below

Powered by WPeMatico

Kerala Govt Unveils Master Plan for Idukki’s Medical College Hospital

Kerala- In a pivotal meeting convened by Kerala Health Minister Veena George and Water Resources Minister Roshi Augustine recently, a significant advancement in healthcare at the Government Medical College Hospital (MCH) in Idukki, Kerala, was announced.

The announcement calls for expediting steps to acquire 50 acres of land earmarked for the expansion plans of MCH and subsequently handing it over to the Directorate of Medical Education, along with the District Collector, ensuring soil testing and all ancillary and mandatory investigations.

Besides, cutting-edge facilities like modular operation theatres will be incorporated with the funding of ₹1.5 crores from the MP fund, which will later be handed over to the Kerala Medical Services Corporation.

However, construction is underway for the women’s hostel, compound wall, streetlights, and installation of an 11-kV feeder line which is expected to be completed within a month. Furthermore, plans for solid waste disposal and the construction of a new block for a nursing college are also included.

Speaking to The Hindu, Ms George in her statement has said that “a Special Purpose Vehicle would be created for the preparation of the master plan”.

“The attendance of medical faculty as well as non-faculty staff be ensured in the institution”, Ms George further added in her statement.

Meanwhile, Mr Augustine stated that “the construction of the road from the Cheruthioni bus stand to the MCH be commenced immediately. The civil, mechanical and electrical works in the new block of the hospital will be taken up soon”.

The meeting was also headed by the Principal Secretary (Health), State Mission Directors of the National Health Mission, the Director of Medical Education, the Director of Health Services and other senior health officials.

The Master Plan of the Government of Kerala will enhance both the infrastructure requirements and the standard of medical services in the region.

Powered by WPeMatico

Pre-natal sex determination racket exposed, 3 held

In a significant breakthrough, police teams from Ghaziabad and Sonipat exposed a pre-natal sex determination racket operating within the premises of Shiva Ultrasound, a registered centre in Ghaziabad.

The accused had allegedly been facilitating couples from Haryana and neighbouring states for illicit sex determination tests, charging a hefty fee of Rs 30,000.

For more information click on the link below:

Powered by WPeMatico

Fake drugs racket busted in Uttarakhand

Two people were arrested here on Thursday and a consignment of spurious drugs worth Rs 43 lakh was seized from them by a team of Telangana Police, officials said.

Those arrested include the owner of the factory where the medicines were manufactured, Hyderabad’s Drugs Inspector Kiran Kumar Jannu, who accompanied a four-member Telangana Police team to Kotdwar, told PTI.
For more information click on the link below:

Powered by WPeMatico

Consumer Court absolves Max Hospital, Cardio-Diabetologist of medical negligence over alleged delay in treatment

The Delhi state consumer disputes redressal commission has absolved Max Super Speciality Hospital, a senior consultant physician & cardio-diabetologist and others in a case alleging medical negligence over the delay in admitting a patient and not providing timely medical treatment resulting in paralysis on the left side of his body and ongoing seizures.

The commission, led by Justice Sangita Dhingra Sehgal delivered the decision on 12th January 2024 noting that the complainant failed to establish negligence or deficiency in service on the part of Max Super Speciality Hospital and no lackadaisical approach of the treating doctors were found.

For more information click on the link below:

Powered by WPeMatico

NPPA Fixes Ceiling Price Of 6 Scheduled Formulations, Details

New Delhi: Through a recent notification, the National Pharmaceutical Pricing Authority (NPPA) has fixed the ceiling price of 6 scheduled formulations under the Drugs (Prices Control) Order, 2013 (NLEM 2022).

The list includes the combination drug Darunavir (600mg) plus Ritonavir (100mg), Nicotine (for nicotine replacement therapy), Levonorgestrel, Cholecalciferol, and the combination drug Tenofovir Disproxil Fumarate plus Lamivudine plus Dolutegravir.

Scheduled formulation means any formulation, included in the First Schedule whether referred to by generic versions or brand names (mainly products covered under the National List of Essential Medicines are Scheduled Formulation). In other words, all medicines that are covered in the National List of Essential Medicine, which are notified in Schedule 1, by the Govt. are scheduled formulation.

“Ceiling Price” refers to a price fixed by the Government for Scheduled Formulations in accordance with the provisions of the drugs (prices control) order, 2013. The ceiling Price is the Maximum Price to Retailer (excluding Taxes, if any)for the given product.

The notice further in the exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17, and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated 30th May 2013 and S.O. 5249(E) dated 11th November 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) has fixed the prices as specified in column (5) of the table herein below as ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the Scheduled formulation specified in the corresponding entry in column (2) of the said Table with the dosage form and strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

Sl.

No.

Name of the Scheduled Formulation

Dosage form and strength

Unit

Ceiling

Price (Rs.)

(1)

(2)

(3)

(4)

(5)

1

Darunavir (A) +Ritonavir (B)

Tablet 600mg (A) + 100mg (B)

1 Tablet

146.45

2

Nicotine (for nicotine replacement therapy)

Oral Dosage forms 2mg Pastille

1 Pastille

7.12

3

Nicotine (for nicotine replacement therapy)

Oral Dosage forms 4mg Pastille

1 Pastille

7.83

4

Levonorgestrel

Tablet 1.5mg

1 Tablet

75.35

5

Cholecalciferol

Solid oral dosage form 1000 IU

Sachet/Granuels/Powder

1 Gram

23.14

6

Tenofovir Disproxil

Fumarate + Lamivudine + Dolutegravir

Tablet 300mg + 300mg + 50 mg

1 Tablet

114.98

The notification further added,

(j) All manufacturers of scheduled formulation, selling the branded or generic or both versions of scheduled formulations at a price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any.

(k) All the existing manufacturers of the above-mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(l) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above-said table.

(m) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from the date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to the State Drug Controller and dealers.

(n) As per para 24(4) of DPCO 2013, every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

(o) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2(1)(u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

(p) The manufacturers of the above-said scheduled formulations shall furnish a quarterly returns to the NPPA, in respect of production/import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and/or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

(q) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.

(r) Consequent to the issue of the ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above-said date of notification, stand(s) superseded.

Powered by WPeMatico